131 related articles for article (PubMed ID: 17766002)
1. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
[TBL] [Abstract][Full Text] [Related]
2. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
3. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Park YH; Lee SY; Lee JS
Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
[TBL] [Abstract][Full Text] [Related]
4. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
[TBL] [Abstract][Full Text] [Related]
5. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
7. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
[TBL] [Abstract][Full Text] [Related]
9. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
Takane H; Miyata M; Burioka N; Kurai J; Fukuoka Y; Suyama H; Shigeoka Y; Otsubo K; Ieiri I; Shimizu E
Ther Drug Monit; 2007 Oct; 29(5):666-8. PubMed ID: 17898662
[TBL] [Abstract][Full Text] [Related]
10. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
11. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
[TBL] [Abstract][Full Text] [Related]
12. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
Rohrbacher M; Kirchhof A; Skarke C; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Mar; 7(2):167-76. PubMed ID: 16515396
[TBL] [Abstract][Full Text] [Related]
13. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
[TBL] [Abstract][Full Text] [Related]
14. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
15. [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
Takane H
Yakugaku Zasshi; 2011; 131(11):1589-94. PubMed ID: 22041697
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
17. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
Yamamoto N; Takahashi T; Kunikane H; Masuda N; Eguchi K; Shibuya M; Takeda Y; Isobe H; Ogura T; Yokoyama A; Watanabe K
Clin Pharmacol Ther; 2009 Feb; 85(2):149-54. PubMed ID: 18685565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
